StemSynergy Therapeutics (United States)

Recent papers from StemSynergy Therapeutics (United States)

1. Nuclear CK1α as an integral component of the WNT/β-catenin transcriptional complex is required in WNT-driven tumor-initiating cellsCell Communication and Signaling · 2026
2. Data from Protein Kinase D–Dependent Downregulation of Immediate Early Genes through Class IIA Histone Deacetylases in Acute Lymphoblastic Leukemia2023
3. Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumorsScience Signaling · 2017
4. Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal PolyposisPLoS ONE · 2014
5. The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast CancerPLoS ONE · 2013
6. Targeting the Wnt Pathway in Synovial Sarcoma ModelsCancer Discovery · 2013
7. A Biochemical Screen for Identification of Small-Molecule Regulators of the Wnt Pathway Using Xenopus Egg ExtractsSLAS DISCOVERY · 2011
8. Efficacy of various drugs in the prevention of posterior capsule opacification: Experimental study of rabbit eyesJournal of Cataract & Refractive Surgery · 2004
9. Patient Outcomes after Reoperation on the Lumbar Spine*Journal of Bone and Joint Surgery · 1996
10. Clinical Applications of Otoacoustic EmissionsJournal of Speech Language and Hearing Research · 1991